Vericel Co. (NASDAQ:VCEL) Stock Holdings Boosted by Townsquare Capital LLC

Townsquare Capital LLC lifted its position in Vericel Co. (NASDAQ:VCEL) by 47.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 50,861 shares of the biotechnology company’s stock after buying an additional 16,385 shares during the period. Townsquare Capital LLC owned approximately 0.10% of Vericel worth $2,149,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of VCEL. FMR LLC raised its position in Vericel by 1.0% in the third quarter. FMR LLC now owns 2,372,812 shares of the biotechnology company’s stock worth $100,251,000 after acquiring an additional 22,461 shares in the last quarter. Conestoga Capital Advisors LLC raised its holdings in shares of Vericel by 1.7% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 2,075,730 shares of the biotechnology company’s stock worth $87,700,000 after purchasing an additional 34,360 shares in the last quarter. Congress Asset Management Co. lifted its stake in Vericel by 37.4% during the third quarter. Congress Asset Management Co. now owns 1,291,720 shares of the biotechnology company’s stock valued at $54,575,000 after purchasing an additional 351,550 shares during the last quarter. Geneva Capital Management LLC boosted its holdings in Vericel by 61.4% during the third quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company’s stock worth $46,660,000 after buying an additional 420,078 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Vericel by 4.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,079,048 shares of the biotechnology company’s stock worth $45,590,000 after buying an additional 47,108 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on VCEL. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Vericel in a research report on Friday, November 8th. TD Cowen increased their price target on Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Canaccord Genuity Group reiterated a “buy” rating and issued a $60.00 target price on shares of Vericel in a report on Tuesday, November 19th. Finally, Canaccord Genuity Group assumed coverage on shares of Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Vericel has an average rating of “Moderate Buy” and an average target price of $59.71.

Insider Activity at Vericel

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the sale, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at $9,142,373.06. The trade was a 7.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the transaction, the director now owns 26,595 shares in the company, valued at $1,595,700. This represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,666 shares of company stock valued at $1,350,764. Insiders own 5.20% of the company’s stock.

Vericel Price Performance

Shares of VCEL opened at $58.14 on Friday. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of 969.00 and a beta of 1.66. The business’s 50-day moving average is $47.35 and its 200-day moving average is $47.35. Vericel Co. has a fifty-two week low of $32.31 and a fifty-two week high of $61.49.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.03. The firm had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. Equities research analysts expect that Vericel Co. will post 0.13 earnings per share for the current fiscal year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.